Novozymes A/S (OTCMKTS:NVZMY) Shares Gap Up – Here’s Why

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $59.62, but opened at $62.25. Novozymes A/S shares last traded at $62.2355, with a volume of 934 shares changing hands.

Analyst Ratings Changes

Several research analysts have recently weighed in on NVZMY shares. Rothschild & Co Redburn raised shares of Novozymes A/S to a “strong-buy” rating in a report on Friday, March 27th. Zacks Research raised Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Finally, Kepler Capital Markets upgraded Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

Get Novozymes A/S alerts:

Check Out Our Latest Stock Report on NVZMY

Novozymes A/S Stock Up 3.4%

The stock’s fifty day moving average price is $59.25 and its 200 day moving average price is $60.27. The company has a current ratio of 1.67, a quick ratio of 1.03 and a debt-to-equity ratio of 0.27. The stock has a market cap of $25.84 billion, a P/E ratio of 42.11, a price-to-earnings-growth ratio of 1.12 and a beta of 0.95.

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.32 billion. Novozymes A/S had a return on equity of 6.52% and a net margin of 14.22%. As a group, research analysts forecast that Novozymes A/S will post 2.43 earnings per share for the current fiscal year.

About Novozymes A/S

(Get Free Report)

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).

See Also

• Five stocks we like better than Novozymes A/S
• From Quantum to Clothing: Insider Trades Hit 3 Big Names
• ASML’s Chip Dominance Runs Into New Silicon Boundaries
• Why These South Korea-Focused ETFs Have More Than Doubled in 2026
• Frozen Assets: How Super Micro Puts AI Heat on Ice

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.